Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene

Cancer Gene Therapy

Volumn 7, Issue 7, 2000, Pages 1023-1033

  Xiang, Jim ^a,c   Chen, Yue ^b   Moyana, Terence ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Saskatoon Cancer Center   (Canada)

Author keywords

Cancer vaccine; Engineered tumor cell; Established tumor; Recombinant adenovirus

Indexed keywords

DNA VACCINE; HLA B7 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CONTROLLED STUDY; GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION; VACCINATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA;

EID: 0343953049     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700195     Document Type: Article

References (53)

1. Blankenstein T, Qin Z, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor gene transfer. J Exp Med. 1991;173:1047-1052.
2. Qi Y, Chen Y, Xiang J. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J Interferon Cytokine Res. 1996;16:771-776.
3. Koshita Y, Lu Y, Fujii S, et al. Efficiency of TNF-α gene-transduced tumor cells in treatment of established in vivo tumor. Int J Cancer. 1995;63:130-135.
4. Colombo M, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumor-igenicity of a murine adenocarcinoma in vivo. J Exp Med. 1991;173:889-897.
5. Allione A, Consalvo M, Manni P, Cavallo F, Giovarelli M, Forni G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF, GMCSF, and IFN gene or admixed with conventional adjuvants. Cancer Res. 1994;54:6022-6026.
6. Linsley P, Ledbetter J. The role of CD28 receptor during T cell responses to antigen. Annu Rev Immunol. 1993;11: 191-212.
7. Schwartz R. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in IL-2 production and immunotherapy. Cell. 1992;71:1065-1068.
8. Hathcock K, Laszlo C, Pucillo C, Linsley P, Hodes R. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994;180:631-640.
9. Cayeux S, Beck C, Dorken B, Blankenstein T. Coexpression of IL-4 and B7-1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther. 1996;7:525-529.
10. Cayeux S, Richter G, Noffz G, Dorken B, Blankenstein T. Influence of gene-modified (IL-7, IL-7 and B7-1) tumor cell vaccines on tumor antigen presentation. J Immunol. 1997;158:2834-2841.
11. Brody S, Jaffee H, Han S, Wersto R, Crystal R. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther. 1994;5:437-447.
12. Chen S, Shine H, Goodman J, Grossman R, Woo A. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
13. Bett A, Haddara W, Prevec L, Graham F. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early region 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
14. Addison C, Braciak T, Ralston R, Muller W, Gauldie J, Graham F. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA. 1995;92:8522-8526.
15. Zhang J, Hu C, Geng Y, Blatt L, Taylor M. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther. 1997;3:31-38.
16. Levraud J, Duffour M, Cordier L, Perricaudet M, Haddada H, Kourilsky P. IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL. J Immunol. 1997;158:3335-3343.
17. Xiang J, Qi Y, Chen Y. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF. Cancer Gene Ther. 1997;4:353-358.
18. Wright P, Zheng C, Moyana T, Xiang J. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/TNF induces significant tumor regression. Cancer Gene Ther. 1998;5:371-379.
19. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm. 1999;14:49-56.
20. Xiang J, Moyana T, Karla J, Hamilton T, Qi Y. Construction and characterization of a high-affinity chimeric anti-colorectal carcinoma antibody ccM4. Mol Biother. 1992;4: 174-183.
21. 2 and tumor necrosis factor. J Biotechnol. 1997;53:3-12.
22. + suppressor T cells. Cancer Res. 1989; 49:1649-1654.
23. Torre-Am G, Beauchamp R, Koeppen H, et al. A highly immunogenic tumor transfected with a murine TGF-β cDNA escapes immune surveillance. Proc Natl Acad Sci USA. 1990;87:1468-1490.
24. Aruga A, Aruga K, Tanigawa D, Bishop V, Sondak K, Chang A. Type 1 vs type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol. 1997;159: 664-671.
25. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993;53:5610-5612.
26. Tartour E, Latour S, Mathiot C, et al. Variable expression of CD3-ζ chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer. 1995;63:205-212.
27. Strand S, Hofmann W, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med. 1996;2: 1361-1366.
28. Agrawal B, Krantz M, Reddish M, Longenecker M Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med. 1998;4:43-49.
29. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA. 1998;95:1178-1183.
30. Singh S, Ross S, Acena M, Rowley D, Schreiber H. Stroma is critical for prevention or permitting immunological destruction of antigenic cancer cells. J Exp Med. 1992;175: 139-146.
31. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725-729.
32. Ghosh P, Komschies K, Cippitelli M, et al. Gradual loss of Th1 population in spleen of mice during progressive tumor growth. J Natl Cancer Inst. 1995;87:1478-1483.
33. Khar A, Kausalya S, Kamal M. AK-5 tumor-induced modulation of host immune function: upregulation of Th1-type cytokine response mediates early tumor regression. Cytokines Mol Ther. 1996;2:39-46.
34. Hu H, Urba W, Fox B. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol. 1998;161:3033-3041.
35. Lee P, Zeng D, McCaulay A, et al. T helper 2-dominant anti-lymphoma immune response is associated with fatal outcome. Blood. 1997;90:1611-1617.
36. Lowes M, Bishop G, Crotty K, Barnetseon R. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol. 1997;108:914-919.
37. Li Y, McGowan P, Hellstrom I, Hellstrom K, Chen L. Costimulation of tumor-reactive CD4 and CD8 T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994;153:421-428.
38. Golumbek P, Lazenby H, Levitsky E, et al. Treatment of established renal cancer by tumor cells engineered to secrete IL-4. Science. 1991;254:713-716.
39. Dranoff G, Jeffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine GMCSF stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
40. r. Hum Antibod Hybridomas. 1996;7:21-26.
41. Clary B, Coveney E, Philip R, et al. Inhibition of established pancreatic cancers following specific active immunotherapy with IL-2 gene-transduced tumor cells. Cancer Gene Ther. 1997;4:97-104.
42. Connor J, Bannerji R, Saito S, Heston W, Fair W, Giboa E. Regression of bladder tumors in mice treated with IL-2 gene-modified tumor cells. J Exp Med. 1993;177:1127-1134.
43. Visse E, Siesjo P, Widegren B, Sjogren H. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with IFN, IL-7, or B7-1-transfected tumor cells. Cancer Gene Ther. 1999;6:37-44.
44. Tanaka H, Yoshizawa H, Yamaguchi Y, et al. Successful adoptive immunotherapy of murine poorly immunogenic tumors with specific effector cells generated from gene-modified, tumor-primed lymph node cells. J Immunol. 1999;162:3574-3582.
45. Fallarino F, Ashikari A, Boon T, Gajewski T. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12 but not B7-1-transfected tumor cells. Int J Immunol. 1997;9:1259-1269.
46. Sarraf C. Tumor necrosis factor and cell death in tumors. Int J Oncol. 1994;5:1333-1339.
47. Tracey K, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45: 491-503.
48. 3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat Med. 1998;4:408-414.
49. Denekamp J. Angiogenesis, neovascular proliferation, and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993;66:181-196.
50. Sherry B, Tekamp-Olson, Gallegos C, et al. Resolution of the two components of macrophage inflammatory protein 1 and cloning and characterization of one of those components, macrophage inflammatory protein 1β. J Exp Med. 1988;168:2251-2259.
51. Cassatella M, Gasperini S, Calzetti F, Bertagnin A, Luster A, McDonald P. Regulated production of the interferon-γ-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol 1997;27:111-116.
52. Taub D, Longo D, Murphy W. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues of human peripheral blood lymphocytes-SCID mice. Blood. 1996;87:1423-1431.
53. Tedla N, Wang H, McNeil H, et al. Regulation of T lymphocyte trafficking into lymph nodes during an immune response by the chemokines macrophage inflammatory protein (MIP)-1α and MIP-1β. J Immunol 1998;161:5663-5672.